Last reviewed · How we verify
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.
Details
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 79 |
| Start date | Fri Aug 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun May 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- HER-2 Negative Breast Cancer
Interventions
- utidelone injection
- Bevacizumab
Countries
China